IP Library › Granted Patent US 12,343,157
Granted Patent B2
US 12,343,157 · App. 17/229,861 · Granted Jul 1, 2025

Assessing motivated attention with cue reactivity

Inventor: Scott Burwell (Minneapolis, MN)
A61B5/378A61B5/31A61B5/372A61B5/384A61B5/0006A61B2560/0431
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,343,157
App. No.
17/229,861
Granted
Jul 1, 2025
Kind
B2
Abstract

A system may include a portable EEG headset configured to capture user EEG signals, a computing device having a graphical user interface, and one or more processors. The one or more processors may be configured to execute instructions to (a) display a sequence of images on the graphical user interface; (b) receive, from the portable EEG headset, user EEG signals that are time-synchronized with the display of the sequence of images; (c) extract from the user EEG signals, one or more event-related potential (ERP) peaks associated with each image; (d) quantify one or more affect-related measures associated with the one or more ERP peaks; and (e) compare the quantified one or more affect-related measures to baseline data to determine a risk to the user.

Claims (38)

1. A system comprising:

a portable computing device having (a) a graphical user interface for displaying images, (b) a device transceiver, and (c) a computing device processor; and

a portable electroencephalographic (EEG) headset having (i) a plurality of electrodes configured to capture electrical neural signals of a user wearing the portable EEG headset, (ii) signal processing circuitry configured to create digital information from the captured electrical neural signals; (iii) a headset processor, and (iv) a headset transceiver configured to exchange information with the device transceiver;

wherein either or both of the computing device processor and the headset processor executes instructions to:

capture, during a first stage of treatment for substance abuse by the user, during which first stage the user is receiving a first type of therapy, baseline data by displaying a first sequence of images on the graphical user interface; receiving the digital information, simultaneously with and in a time-synchronized manner relative to the displayed first sequence of images; extracting from the digital information, baseline event-related potential (ERP) peaks associated with each image in the first sequence of images, wherein the baseline ERP peaks are time-synchronized to within 1500 ms of the presentation of each corresponding image in the first sequence of images; quantifying affect-related baseline measures associated with the baseline ERP peaks, each baseline affect-related measure comprising a pleasantness aspect and an intensity aspect;

capture, during a second stage of treatment for substance abuse by the user, comparison data by displaying a second sequence of images on the graphical user interface; receiving the digital information, simultaneously with and in a time-synchronized manner relative to the displayed second sequence of images; extracting from the digital information, comparison ERP peaks associated with each image in the second sequence of images, wherein the comparison ERP peaks are time-synchronized to within 1500 ms of the presentation of each corresponding image in the second sequence of images; quantifying affect-related comparison measures associated with the comparison ERP peaks, each comparison affect-related measure comprising the pleasantness aspect and the intensity aspect;

compare the quantified comparison affect-related measures to the baseline affect-related measures to determine risk to the user of relapse to substance abuse; and

based on the determined risk, provide to a clinician involved in treatment for substance abuse of the user, an indication that either the first type of therapy should be maintained or therapy should be transitioned from the first type of therapy to a second type of therapy that is different than the first type of therapy.

2. The system of claim 1 , further comprising a centralized computing facility with a data store coupled to the portable computing device by a network, through the device transceiver, the data store stores the baseline data.

3. The system of claim 1 , wherein each image in the first sequence of images is temporally separated from a preceding image or a succeeding image by a delay.

4. The system of claim 3 , wherein the delay is approximately 250 ms or approximately 500 ms.

5. A system comprising:

a portable electroencephalographic (EEG) headset, configured to capture EEG signals from a user who is undergoing treatment;

a computing device having a graphical user interface;

one or more processors that execute instructions to:

display a sequence of images on the graphical user interface, each image in the sequence of images having associated therewith an expected affect-related measure of pleasantness and intensity that is expected to evoke an event-related potential (ERP) peak that is greater than a first image-specific threshold and less than a second image-specific threshold;

receive, from the portable EEG headset, the EEG signals in a manner that is simultaneous to and time-synchronized with the display of each image in the sequence of images;

extract from the EEG signals, one or more ERP peaks associated with each image, wherein the one more ERP peaks are time-synchronized to within 1500 ms of the display on the graphical user interface of each image in the sequence of images;

for each image, compare the one or more ERP peaks to the respective first image-specific threshold and to the respective second image-specific threshold;

based on the comparing for each image, determine a risk to the user; and

based on the determined risk, provide to a clinician who is treating the user an indication that medication should be added or altered, treatment time should be extended or truncated or type of treatment should be adjusted.

6. The system of claim 5 , wherein the risk to the user comprises one of a proclivity to a maladaptive behavior or substance use, or a relapse to use of a substance or engagement of a behavior.

7. The system of claim 5 , wherein the first image-specific threshold and the second image-specific threshold are characterized with reference to an electrode on the portable EEG headset.

8. The system of claim 7 , wherein the first image-specific threshold and second image-specific threshold are further characterized with reference to a normative population distribution.

9. The system of claim 8 , wherein at least one of the first image-specific threshold or the second image-specific threshold corresponds to population-based expected values based on normative ratings of affective pleasantness and intensity of the respective image in the sequence of images.

10. The system of claim 7 , wherein the first image-specific threshold and the second image-specific threshold are further characterized with reference to historical data associated with the user.

11. The system of claim 5 , wherein extracting the one or more ERP peaks associated with each image comprises identifying a peak or trough within a specified period of time relative to display of the respective image on the graphical user interface.

12. The system of claim 11 , wherein the specified period of time is within a range of approximately 150 milliseconds to 1500 milliseconds.

13. A method of treating a user for an addictive or motivational salience disorder, the method comprising:

providing a portable computing device having (a) a graphical user interface for displaying images, (b) a device transceiver, and (c) a computing device processor; and a portable electroencephalographic (EEG) headset having (i) a plurality of electrodes configured to capture electrical neural signals of a user wearing the portable EEG headset, (ii) signal processing circuitry configured to create digital information from the captured electrical neural signals; (iii) a headset processor, and (iv) a headset transceiver configured to exchange information with the device transceiver;

capturing, with the EEG headset and the portable computing device, baseline data by displaying a first sequence of images on the graphical user interface; receiving the digital information simultaneously to and time-synchronized with the displayed first sequence of images; extracting from the digital information, baseline event-related potential (ERP) peaks associated with each image in the first sequence of images, wherein the baseline ERP peaks are time-synchronized to within 1500 ms of the presentation of each corresponding image in the first sequence of images; quantifying affect-related baseline measures associated with the baseline ERP peaks, each baseline affect-related measure comprising a pleasantness aspect and an intensity aspect;

after capturing the baseline data, delivering a first type of therapy to the user during a first stage of treatment, wherein the first stage of treatment comprises days, weeks or months;

after the first stage of treatment, capturing, with the EEG headset and the portable computer device, comparison data by displaying a second sequence of images on the graphical user interface; receiving the digital information simultaneously to and time-synchronized with the displayed second sequence of images; extracting from the digital information, comparison ERP peaks associated with each image in the second sequence of images, wherein the comparison ERP peaks are time-synchronized to within 1500 ms of the presentation of each corresponding image in the second sequence of images; quantifying affect-related comparison measures associated with the comparison ERP peaks, each comparison affect-related measure comprising the pleasantness aspect and the intensity aspect;

comparing the quantified comparison affect-related measures to the baseline affect-related measures to determine a change; and

during a second stage of treatment, when the change is less than a threshold amount, continuing to deliver the first therapy to the user, and when the change is greater than the threshold amount, delivering a second therapy to the user that is different than the first therapy.

14. The method of claim 13 , wherein the threshold corresponds to a population-level expected value that is based on a normative rating of affective pleasantness and intensity for a corresponding image.

15. The method of claim 13 , wherein the first type of therapy comprises at least one of a pharmaceutical treatment therapy, psychological or behavior modification therapy, or neuromodulation treatment.

16. The method of claim 13 , wherein the second type of therapy comprises displaying to the user a report, graph, or chart of historical change in affect-related measures of the user's physiological response to images in the first sequence or the second sequence.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2025
From: BURWELL, SCOTT J.
To: NEUROTYPE INC.
Reel/Frame 071106/0135 →
Continuity (3)
Provisional Application 63010040 · Apr 14, 2020
Provisional Application 63010042 · Apr 14, 2020
Related Publication 20210315508A1 · Oct 14, 2021
References Cited (177)
US 5730146A · Itel et al. · 1998 [cited by applicant]
US 6186145B1 · Brown · 2001 [cited by examiner]
US 6572562B2 · Marshall · 2003 [cited by applicant]
US 6983184B2 · Price · 2006 [cited by applicant]
US 8239000B1 · Morris et al. · 2012 [cited by applicant]
US 8386312B2 · Pradeep et al. · 2013 [cited by applicant]
US 8392250B2 · Predeep et al. · 2013 [cited by applicant]
US 8392255B2 · Pradeep et al. · 2013 [cited by applicant]
US 8762202B2 · Pradeep et al. · 2014 [cited by applicant]
US 8805489B1 · Ofek · 2014 [cited by applicant]
US 9113801B2 · Dilorenzo · 2015 [cited by applicant]
US 9336535B2 · Pradeep et al. · 2016 [cited by applicant]
US 9339227B2 · D'Arcy et al. · 2016 [cited by applicant]
US 9558425B2 · Wang et al. · 2017 [cited by applicant]
US 9603564B2 · Forbes · 2017 [cited by applicant]
US 9886981B2 · Pradeep et al. · 2018 [cited by applicant]
US 10108264B2 · Le et al. · 2018 [cited by applicant]
US 11311228B1 · Oakley · 2022 [cited by examiner]
US 20030158497A1 · Graham · 2003 [cited by examiner]
US 20050273017A1 · Gordon · 2005 [cited by applicant]
US 20070060831A1 · Le et al. · 2007 [cited by applicant]
US 20080065468A1 · Berg et al. · 2008 [cited by applicant]
US 20090062629A1 · Pradeep et al. · 2009 [cited by applicant]
US 20100156617A1 · Nakada · 2010 [cited by examiner]
US 20110118618A1 · John · 2011 [cited by examiner]
US 20120130800A1 · Pradeep et al. · 2012 [cited by applicant]
US 20120259240A1 · Llewellynn et al. · 2012 [cited by applicant]
US 20120330178A1 · Kraft · 2012 [cited by examiner]
US 20130073396A1 · Pradeep et al. · 2013 [cited by applicant]
US 20130131535A1 · Sun et al. · 2013 [cited by applicant]
US 20130144184A1 · Regini · 2013 [cited by examiner]
US 20140163408A1 · Kocher · 2014 [cited by examiner]
US 20150248470A1 · Coleman et al. · 2015 [cited by applicant]
US 20150257673A1 · Lawrence · 2015 [cited by examiner]
US 20150297109A1 · Garten et al. · 2015 [cited by applicant]
US 20170347907A1 · Le et al. · 2017 [cited by applicant]
US 20190059770A1 · Gunasekar · 2019 [cited by examiner]
US 20190247654A1 · Alyagon et al. · 2019 [cited by applicant]
EP 2695124A1 · 2014 [cited by applicant]
EP 2906114A1 · 2015 [cited by applicant]
EP 3030151A1 · 2016 [cited by applicant]
EP 3143933B1 · 2018 [cited by applicant]
WO WO2008030542A3 · 2008 [cited by applicant]
WO WO2013177592A3 · 2013 [cited by applicant]
WO WO2014170897A1 · 2014 [cited by applicant]
WO WO2015017563A1 · 2015 [cited by applicant]
WO WO2016143759A1 · 2016 [cited by applicant]
Littel, M., Euser, A. S., Munafò, M. R., Franken, I. H. A. (2012). Electrophysiological indices of biased cognitive processing of substance-related cues: A meta-analysis. Neuroscience Biobehavioral Reviews, 36(8), 1803-… [cited by examiner]
Luijten, M., Kleinjan, M., & Franken, I. H. (2016). Event-related potentials reflecting smoking cue reactivity and cognitive control as predictors of smoking relapse and resumption. Psychopharmacology, 233(15-16), 2857-… [cited by examiner]
Habelt, B., Arvaneh, M., Bernhardt, N., & Minev, I. (2020b). Biomarkers and neuromodulation techniques in substance use disorders. Bioelectronic Medicine, 6(1). doi.org/10.1186/s42234-020-0040-0 (Year: 2020). [cited by examiner]
AAN, “Coding FAQs,” retrieved from https://www.aan.com/practice/billing-and-coding/coding-faqs/, 5 pages. [cited by applicant]
Allenby et al., “Neural cue reactivity during acute abstinence predicts short-term smoking relaps,” Addict. Biol. 2019, 1-9, 9 pages. [cited by applicant]
American Academy of Neurology, “ Long-term EEG Monitoring FAQs,” retrieved from https://www.aan.com/siteassets/home-page/tools-and-resources/practicing-neurologist—administrators/billing-and-coding/coding-faqs/eeg-faq-o… [cited by applicant]
Anker et al., “Casal Network Modeling of the Determinants of Drinking Behavior in Comorbid Alcohol Use and Anxiety Disorder,” Alcohol. Clin. Exp. Res. 2019, 43(1): 91-97, 7 pages. [cited by applicant]
Anker et al., A network approach to modeling comorbid internalizing and alcohol use disorders, J. Abnorm. Pscyhol. 2017; 126(3): 325-339, 15 pages. [cited by applicant]
Bach et al., “Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone,” Addict. Biol. 2019, 1-11, 11 pages. [cited by applicant]
Berridge et al., “Liking, wanting, and the incentive-sensitization theory of addiction,” Am. Psychol. 2016, 71(8): 670-679, 17 pages. [cited by applicant]
Bigdely-Shamlo et al., “Automated EEG mega-analysis II: Cognitive aspects of event related features,” NeuroImage 2019, retrieved from https://doi.org/10.1016/j.neuroimage.2019.116054, 40 pages. [cited by applicant]
Biosemi, “Start your analysis with clean signals from BioSemi systems,” retrieved from https://www.biosemi.com/, last visited Mar. 8, 2021, 1 page. [cited by applicant]
Bouchery et al.,“Type of health insurance and the substance abuse treatment gap,” J. Subst. Abuse Treat 2012, 42: 289-300, 12 pages. [cited by applicant]
Brain Products, “Products by Application,” retrieved from https://www.brainproducts.com/products_by_apps.php?aid=5, last visited Mar. 8, 2021, 1 page. [cited by applicant]
Briggs et al., “Affective picture processing and motivational relevance: Arousal and valence effects on ERPs in an oddball task,” International J of Psychophysiology 2009, 17: 299-306, 8 pages. [cited by applicant]
Brooke, “SUS—A quick and dirty usability scale,” retrieved from www.TBISTAffTraining.info, 8 pages. [cited by applicant]
Burwell et al., “Does Electroencephalogram Phase Variability Account for Reduced P3 Brain Potential in Externalized Disorders?” Clin Neurophysiol. 2014, 125(10): 2007-2015, 24 pages. [cited by applicant]
Burwell et al., “Reduced premovement positivity during the stimulus-response interval precedes errors: Using single-trial and regression ERPs to understand performance deficits in ADHD,” Psychophysiology 2019, 00(e13392… [cited by applicant]
Burwell, “Setting value-based payment goals-HHS efforts to improve US health care,” N. Engl. J. Med. 2015, 372 (10): 897-899, 3 pages. [cited by applicant]
Carpenter et al., “Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians,” Statist. Med. 2000, 19: 1141-1164, 24 pages. [cited by applicant]
Carretie et al., “EmoMadrid: An emotional pictures database for affect research,” Motivation and Emotion 2019, 43: 929-939, 11 pages. [cited by applicant]
Cinciripini et al., “Benefits of varenicline vs. bupropion for smoking cessation: a Bayesian analysis of the interaction of reward sensitivity and treatment,” Psychopharmacology 2017; 234, 1769-1779. [cited by applicant]
Cofresi et al., “Evidence for incentive salience sensitization as a pathway to alcohol use disorder,” Neuroscience and Behavioral Reviews 2019, 107: 897-926. [cited by applicant]
Colaizzi et al., “Mapping sign-tracking and goal-tracking onto human behaviors,” Neuroscience and Biobehavioral Reviews 2020, 111: 84-94. [cited by applicant]
Compumedics, NeuroScan, retrieved from https://compumedicsneuroscan.com/, last visited Mar. 8, 2021, 4 pages. [cited by applicant]
Courtney et al., “Neural substrates of cue reactivity: association with treatment outcomes and relapse,” Addict. Biol. 2016; 21(1): 3-22, 29 pages. [cited by applicant]
Debener et al., “How about taking a low-cost, small, and wireless EEG for a walk?” Psychophysiology 2012, 49: 1449-1453, 5 pages. [cited by applicant]
Del Zotto et al., “Electrophysiological evidence of perceived sexual attractiveness for human female bodies varying In waist-to-hip ration,” Cogn. Affect Behav Neurosci 2017, 17: 577-591, 15 pages. [cited by applicant]
Deweese et al., “Cigarette cues capture attention of smokers and never-smokers, but for different reasons,” Drug Alchol. Depend. 2018; 185: 50-57, 8 pages. [cited by applicant]
Di Flumeri et al., “The Dry Revolution: Evaluation of Three Different EEG Dry Electrode Types in Terms of Signal Spectral Features, Mental States Classification and Usability,” Sensors 2019, 19 (1365): 1-21, 21 pages. [cited by applicant]
Emotiv, “Emotiv Epoc,” retrieved from https://www.emotiv.com/epoc/, last visited Mar. 8, 2021, 12 pages. [cited by applicant]
Engelmann et al., “Individual differences in brain responses to cigarette-related cues and pleasant stimuli in young smokers,” Drug Alcohol Depend. 2016, 163: 229-235, 7 pages. [cited by applicant]
Engelmann et al., “Neural substrates of smoking cue reactivity: a meta-analysis of fMRI studies,” Neuroimage 2012, 60(1): 252-262, 30 pages. [cited by applicant]
Farwell, “Brain fingerprinting: a comprehensive tutorial review of detection of concealed information with event-related brain potentials,” Cogn. Neurodyn. 2012, 6: 115-154. [cited by applicant]
Faulkner, “Beyond the five-user assumption: Benefits of increased sample sizes in usability testing,” Behavior Research Methods, Instruments, & Computers 2003, 35(3): 379-383, 5 pages. [cited by applicant]
Fedoroff et al., “Evaluation of the Yale-Brown Obsessive Compulsive Scale (YBOCS-hd) for heavy drinking with mild to moderately dependent alcohol abusers,” Alcohol. Clin. Exp. Res. 1999; 23(9): 1477-1483, 7 pages. [cited by applicant]
Frank et al., “Toward Precision Medicine for Smoking Cessation: Developing a Neuroimaging-Based Classification Algorithm to Identify Smokers at Higher Risk for Relapse,” Nicotine & Tobacco Research 2019, 1-8, 8 pages. [cited by applicant]
Franken et al.., “Neurophysiological evidence for abnormal cognitive processing of drug cues in heroin dependence,” Psychopharmacology 2003, 170: 205-212, 7 pages. [cited by applicant]
Garland et al., “Effects of Mindfulness-Oriented Recovery Enhancement on reward responsiveness and opioid cue-reactivity,” Psychopharmacology 2014; 231: 3229-3238, 9 pages. [cited by applicant]
Garland et al., “Mindfulness-Oriented Recovery Enhancement reduces pain attentional bias in chronic pain patients,” Psychother. Psychosom. 2013; 82(5): 311-318, 7 pages. [cited by applicant]
Garland et al., “Mindfulness-Oriented Recovery Enhancement remediates hedonic dysregulation in opioid users: Neural and affective evidence of target engagement,” Sci. Adv. 2019, 5(eaax1569): 1-12, 13 pages. [cited by applicant]
Garland et al., Neurophysiological evidence for remediation of reward processing deficits in chronic pain and opioid misuse following treatment with Mindfulness-Oriented Recovery Enhancement: exploratory ERP findings fr… [cited by applicant]
Gibney et al., “Estimating statistical power for event-related potential studies using the late positive potential,” Psychophysiology 2019, retrieved from https://www.biorxiv.org/content/10.1101/574368v1, 34 pages. [cited by applicant]
Gloss et al.,“Practice advisory: The utility of EEG thera/beta power ration in ADHD diagnosis,” Neurology 2016, 87: 2375-2379, 7 pages. [cited by applicant]
Goldstein, “Nonlinear multilevel models, with an application to discrete response data,” Biometrika 1991, 78: 45-51, 7 pages. [cited by applicant]
Gu, “Incubation of craving: a Bayesian account,” Neuropsychopharmacology 2018; 43: 2337-2339, 3 pages. [cited by applicant]
Haifeng et al., “P300 event-related potential in abstinent methamphetamine-dependent patients,” Physiol. Behav. 2015, 149(1): 142-148, 6 pages. [cited by applicant]
Hendrikse et al., “Attentional biases for food cues in overweight and individuals with obesity: a systematic review of the literature, ” World Obesity 2015, 16: 424-432, 9 pages. [cited by applicant]
Holla et al., “Brain Functional Magnetic Resonance Imaging Cue-reactivity Can Predict Baclofen Response in Alcohol Use Disorders, ” Clin. Psychopharmacol. Neurosci. 2018, 16(3): 290-301, 11 pages. [cited by applicant]
Horndasch, “Cue reactivity towards bodies in anorexia nervosa - common and differential effects in adolescents and adults,” Psychological Medicine 2018; 48(3): 508-18, 11 pages. [cited by applicant]
Ilgen et al., “Abstinence Self-Efficacy and Abstinence 1 Year After Substance Use Disorder Treatment,” J. Consult. Clin. Psychol. 2005; 73(6): 1175-1180, 6 pages. [cited by applicant]
Janes et al., “Brain Reactivity to Smoking Cues Prior to Smoking Cessation Predicts Ability to Maintain Tobacco Abstinence,” Biol. Psychiatry 2010, 67: 722-729, 8 pages. [cited by applicant]
Jasinska et al., “Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies,” Neurosci. Biobehav. Rev. 2014; 38: 1-16, 35 pages. [cited by applicant]
Jiang et al., “Effect of Electro-acupuncture Intervention on Cognition Attention Bias in Heroin Addiction Abstinence-A Dot-probe-based Event-related Potential Study,” Chin. J. Integr. Med. 2011, 17(4): 267-274, 5 pages. [cited by applicant]
Junghofer et al., “ Fleeting images: A new look at early emotion discrimination,” Psychophysiology 2001, 38: 175-178, 4 pages. [cited by applicant]
Karthik et al., “Alcohol-related cue-reactivity predicts abstinence duration in individuals with severe alcohol-use disorders,” Eur. Psychiatry 2017; 41S: S877, 1 page. [cited by applicant]
Keil et al., “Committee report: Publication guidelines and recommendations for studies using electroencephalography and magnetoencephalography,” Psychophysiology 2014; 51: 1-21, 21 pages. [cited by applicant]
Kim et al., “Increased Attentional Bias Toward Visual Cues in Internet Gaming Disorder and Obsessive-Compulsive Disorder: An Event-Related Potential Study,” Frontiers in Psychiatry 2018; 9(315), 9 pages. [cited by applicant]
Koob et al., “Neurobiology of addiction: a neurocircuitry analysis,” Lancet Psychiatry 2016, 3(8): 760-773, 28 pages. [cited by applicant]
Krigolson et al., “Choosing MUSE: Validation of a Low-Cost, Portable EEG System for ERP Research,” Frontiers in Neuroscience 2017, 11(109): 1-10, 10 pages. [cited by applicant]
Kuhn et al., “Common biology of craving across legal and illegal drugs—a quantitative meta-analysis of cue-reactivity brain response,” European J. of Neuroscience 2011; 33: 1318-1326, 9 pages. [cited by applicant]
Kurdi et al., “Introducing the Open Affective Standardized Image Set (OASIS),” Behav. Res. 2017, 49: 457-470, 14 pages. [cited by applicant]
Kwako et al., “Addiction Biomarkers: Dimensional Approaches to Understanding Addiction,” Trends Mol. Med. 2018, 24(2): 121-128, 8 pages. [cited by applicant]
Kwako et al., “Addiction Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders,” Biol. Psychiatry 2016; 80(3): 179-189, 11 pages. [cited by applicant]
Li et al., “Predicting subsequent relapse by drug-related cue-induced brain activation in heroin addiction: an event-related functional magnetic resonance imaging study,” Addict. Biol. 2014, 20: 968-978, 19 pages. [cited by applicant]
Littel et al., “Electrophysiological indices of biased cognitive processing of substance-related cues: A meta-analysis,” Neuroscience and Biobehavioral Reviews 2012, 36: 1803-8016, 14 pages. [cited by applicant]
Liu et al., “Neural Substrate of the Late Positive Potential in Emotional Processing,” J. Neurosci. 2012, 32(42): 14563-14572, 10 pages. [cited by applicant]
Lou et al., “Cue-elicited Craving in Heroin Addicts at Different Abstinent Time: An fMRI pilot study,” Subst. Use & Misuse 2012, 47(6): 631-639, 10 pages. [cited by applicant]
Lubman et al., “Electrophysiological evidence that drug cues have greater salience than other affective stimuli in opiate addiction,” J. Psychopharmacol. 2008, 22(8): 836-842, 7 pages. [cited by applicant]
Lubman et al., “Electrophysicological evidence of the motivational salience of drug cues in opiate addiction,” Psychol. Med. 2007, 37: 1203-1209, 7 pages. [cited by applicant]
Lubman et al., “Responsiveness to drug cues and natural rewards in opiate addiction: associations with later heroin use, ” Arch. Gen. Psychiatry 2009; 66(2): 205-213, 9 pages. [cited by applicant]
Luijten et al., “Event-related potentials reflecting smoking cue reactivity and cognitive control as predictors of smoking relapse and resumption,” Psychopharmacology 2016, 233: 2857-2868, 12 pages. [cited by applicant]
Macniven et al., “Association of Neural Responses to Drug Cues With Subsequent Relapse to Stimuli and Use,” JAMA Netw. Open 2018, 1(8): 1-14, 14 pages. [cited by applicant]
Magura et al., “Predictive Validity of the ASAM Patient Placement Criteria for Naturalistically Matched vs. Mismatched Alcoholism Patients,” American J. on Addicts 2003, 12:386-397, 12 pages. [cited by applicant]
Makeig et al., “Evolving signal processing for brain-computer interfaces,” Proceedings of the IEEE 2021, retrieved from http://dsp.ucsd.edu/˜kreutz/Publications/makeig2012evolving.pdf, 51 pages. [cited by applicant]
Marini et al., “A comparative evaluation of signal quality between research-grade and wireless dry-electrode mobile EEG systems,” J. Neural Eng. 2019, 1-34, 35 pages. [cited by applicant]
Martins et al., “Interactive Effects of Naturalistic Drinking Context and Alcohol Sensitivity on Neural Alcohol Cue-Reactivity Responses,” Alcoholism: Clinical and Experimental Research 2019, 43(8): 1777-1789, 13 pages. [cited by applicant]
Matheus-Roth et al., “Occipital event-related potentials to addiction-related stimuli in detoxified patients with alcohol dependence, and their association with three-month relapse,” BMC Psychiatry 2016, 16: 74-86, 12 p… [cited by applicant]
McHugh et al., “Cue-Induced Craving to Paraphernalia and Drug Images in Opioid Dependence,” The American Journal on Addiction 2016, 25: 105-109, 5 pages. [cited by applicant]
Miccoli et al., “Meet OLAF, a Good Friend of the IAPS! The Open Library of Affective Foods: A Tool to Investigate the Emotional Impact of Food in Adolescents,” PLOS One 2014, 1-22, 22 pages. [cited by applicant]
Miller, “From Volume To Value: Better Ways to Pay for Health Care,” Health Aff. 2009; 28: 1418-1428, 11 pages. [cited by applicant]
Mullen et al., “Real-Time Neuroimaging and Cognitive Monitoring Using Wearable Dry EEG,” IEEE Trans. Biomed. Eng. 2015, 62(11): 2553-2567, 40 pages. [cited by applicant]
Nunes et al., “Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone,” J. Subst. Abuse Treat. 2018, 85: 49-55, 17 pages. [cited by applicant]
Owens et al.,“Neural correlates of tobacco cue reactivity predict duration to lapse and continuous abstinence in smoking cessation treatment,” Addict. Biol. 2018, 23: 1189-1199, 11 pages. [cited by applicant]
Palmieri et al., “Lies in the doctor-patient relationship,” Prim. Care Companion J. Clin. Psychiatry 2009; 11(4): 163-168, 6 pages. [cited by applicant]
Parvaz et al., “Abstinence reverses EEG-indexed attention bias between drug-related and pleasant stimuli in cocaine-addicted individuals,” J. Psychiatry Neurosci. 2017, 42(2):78-86, 9 pages. [cited by applicant]
Parvaz et al., “Incubation of Cue-Induced Craving in Adults Addicted to Cocaine Measured by Electroencephalography,” JAMA Psychiatry 2016; 73(11): 1127-1134, 8 pages. [cited by applicant]
Paulus et al., “The role of interoception and alliesthesia in addiction,” Pharmacol. Biochem. Behav. 2009; 94: 1-7, 7 pages. [cited by applicant]
Petit et al., “Reduced processing of alcohol cues predicts abstinence in recently detoxified alcoholic patients in a three-month follow up period: An ERP study,” Behavioral Brain Research 2015, 282: 84-94, 11 pages. [cited by applicant]
Pickens et al., “Neurobiology of the incubation of drug craving,” Trends Neurosci. 2011; 34(8): 411-20, 10 pages. [cited by applicant]
Proctor et al., “The continuing care model of substance use treatment: what works, and when is ‘enough,’ enough'?,” Psychiatry J. 2014, 1-16, 17 pages. [cited by applicant]
Raduntz, “Signal Quality Evaluation of Emerging EEG Devices,” Frontiers in Physiology 2018; 9(98): 1-12, 12 pages. [cited by applicant]
Ries et al., “A Comparison of Electroencephalography Signals Acquired from Conventional and Mobile Systems,” J. of Neuroscience and Neuroengineering 2014, 3: 10-20, 12 pages. [cited by applicant]
Robinson et al., “Incentive-sensitization and addiction,” Addiction 2001; 96: 103-114, 12 pages. [cited by applicant]
Robinson et al., “The neural basis of drug craving: an incentive-sensitization theory of addiction,” Brain Res. Rev. 1993, 18: 247-91, 45 pages. [cited by applicant]
Sabatinelli et al., “Emotional perception: correlation of functional MRI and event-related potentials,” Cereb. Cortex 2007, 17: 1085-1091, 7 pages. [cited by applicant]
Saunders et al., “Individual variation in resisting temptation; implications for addiction,” Neurosci. Biobehav. Rev. Nov. 2013; 37(0), 49 pages. [cited by applicant]
Schacht et al., “Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review,” Addict. Biol. 2013; 18(1): 121-133, 23 pages. [cited by applicant]
Schupp et al., “The selective processing of briefly presented affective pictures: an ERP analysis,” Pscyhophysiology 2004, 41: 441-449, 9 pages. [cited by applicant]
Schupp et al.,“Affective picture processing: the late positive potential is modulated by motivational relevance,” Pscyhophysiology 2000, 37: 257-261, 5 pages. [cited by applicant]
Silva et al., “Biophysical Aspects of EEG and MEG Generation,” Niedermeyer's Electroencephalography, Oxford University Press, 12 pages. [cited by applicant]
Smith et al., “Regression-based estimation of ERP waveforms: I. The rERP framework,” Psychophysiology 2015, 52 (2): 157-168, 26 pages. [cited by applicant]
Smith et al., “Regression-based estimation of ERP waveforms: II. Nonlinear effects, overlap correction, and practical considerations,” Psychophysiology 2015, 52:169-181, 13 pages. [cited by applicant]
Smyth et al., “Lapse and Relapse Following Inpatient Treatment of Opiate Dependence,” Ir. Med. J. Jun. 2010; 103 (6): 176-9, 1 page. [cited by applicant]
Swan, “The Quantified Self: Fundamental Disruption in Big Data Science and Biological Discovery,” Big Data 2013, 1 (2):85-99, 15 pages. [cited by applicant]
Tomie et al., “Behavioral Characteristics and Neurobiological Substrates Shared by Pavlovian Sign-Tracking and Drug Abuse,” Brain Res Rev. 2008; 58(1): 121-135, 15 pages. [cited by applicant]
Verdejo-Garcia et al., “A Roadmap for Integrating Neuroscience Into Addiction Treatment: A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine,” Fron. Psychiatry 2019; 10: 877… [cited by applicant]
Verdejo-Garcia et al., “The role of interoception in addiction: a critical review,” Neurosci. Biobehav. Rev. 2012, 36: 1857-1869, 13 pages. [cited by applicant]
Versace et al., Beyond cue reactivity: blunted brain responses to pleasant stimuli predict long-term smoking abstinence, Addict. Biol. 2012; 17: 991-1000, 10 pages. [cited by applicant]
Versace et al., “Beyond Cue Reactivity: Non-Drug-Related Motivationally Relevant Stimuli Are Necessary to Understand Reactivity to Drug-Related Cues,” Nicotine & Tobacco Research 2017, 663-669, 7 pages. [cited by applicant]
Versace et al., “Brain Responses to Cigarette-Related and Emotional Images in Smokers During Smoking Cessation: No Effect of Varenicline or Bupropion on the Late Positive Potential,” Nicotine & Tobacco Research 2019, 23… [cited by applicant]
Versace et al., “Heterogeneity in brain reactivity to pleasant and food cues: evidence of sign-tracking in humans,” Soc. Cogn. Affect. Neurosci. 2016; 11: 604-611, 8 pages. [cited by applicant]
Versace et al., “Prequit fMRI responses to pleasant cues and cigarette-related cues predict smoking cessation outcome,” Nicotine Tob. Res. 2014, 16: 697-708, 12 pages. [cited by applicant]
Versace et al., “The reality of ‘food porn’: Larger brain responses to food-related cues than to erotic images predict cue-induced eating,” Psychophysiology 2019; 56: e13309, 13 pages. [cited by applicant]
Virzi, “Refining the Test Phase of Usability Evaluation: How Many Subjects Is Enough?” Human Factors 1992, 34(4): 457-468, 12 pages. [cited by applicant]
Widge et al., “Electroencephalographic Biomarkers for Treatment Response Prediction in Major Depressive Illness: A Meta-Analysis,” Am J Psychiatry 2019, 176(1):44-56, 13 pages. [cited by applicant]
Wilcox et al., “Default mode network deactivation to smoking cue relative to food cue predicts treatment outcome in nicotine use disorder,” Addict. Biol. 2018, 23: 412-424, 13 pages. [cited by applicant]
Witbrodt et al., “Day Hospital and Residential Addiction Treatment: Randomized and Nonrandomized Managed Care Clients,” J. of Consulting and Clinical Psychology 2007, 75(6): 947-959, 13 pages. [cited by applicant]
Witkiewitz et al., Mindfulness-based relapse prevention for alcohol and substance use disorders, J. Cogn. Psychother. 2005, 19(3): 211-228, 19 pages. [cited by applicant]
Wu et al., “An Electroencephalographic signature predicts antidepressant response in major depression,” Nature Biotechnology 2020, 38: 439-447, 20 Pages. [cited by applicant]
Zuckerman et al., “Development of a Sensation-Seeking Scale,” J of Consulting Psychology 1964, 28(6): 477-482, 6 pages. [cited by applicant]
Picton et al., “Guidelines for using human event-related potentials to study cognition: Recording standards and publication criteria,” Psychophysiology 2000; 37(2000):127-152, 26 pages. [cited by applicant]
Muse, “Neurofeedback EEG Device—How it Works,” retrieved from https://choosemuse.com/how-it-works/, last visited Oct. 26, 2021, 8 pages. [cited by applicant]
Koob et al., “Neurocircuitry of Addiction,” Neuropsychopharmacology Reviews 2010, 35: 217-238, 22 pages. [cited by applicant]
Fazei-Rezai et al., “P300 brain computer interface: current challenges and emerging trends,” Frontiers in Neuroengineering 2012, 5(14): 1-14, 14 pages. [cited by applicant]
Carter et. al., “Meta-analysis of cue-reactivity in addiction research,” Addiction 1999, 94(3): 327-240, 15 pages. [cited by applicant]
Jiang et al., “Effect of Electro-acupuncture Intervention on Cognition Attention Bias in Heroin Addiction Abstinence-A Dot-probe-based Even-related Potential Study, ”Chin. J. Integr. Med, 2011, 17(4): 267-274, 5 pages. [cited by applicant]
Neurosity, “Crown,” retrieved from https://neurosity.co/, last visited Oct. 28, 2021, 2 pages. [cited by applicant]
Ravi, “Train your Mind and Free your Code,” retrieved from https://medium.com/an-idea/train-your-mind-and-free-your-code-5bd635b91ebb, last visited Oct. 28, 2021, 5 pages. [cited by applicant]
Neurosity, “Notion 2,” retrieved from https://neurosity.co/, last visited Mar. 8, 2021, 6 pages. [cited by applicant]